       Document 0152
 DOCN  M9640152
 TI    Antiretroviral activity of stavudine (2',3'-didehydro-3'-deoxythymidine,
       D4T).
 DT    9604
 AU    Riddler SA; Anderson RE; Mellors JW; Division of Infectious Diseases,
       University of Pittsburgh Medical; Center, PA 15213, USA.
 SO    Antiviral Res. 1995 Jun;27(3):189-203. Unique Identifier : AIDSLINE
       MED/96145330
 AB    Stavudine, 2',3'-didehydro-3'-deoxythymidine (D4T), is a potent
       inhibitor of HIV-1 reverse transcriptase in vitro. In clinical studies,
       stavudine has excellent oral bioavailability in excess of 80%. The
       dose-limiting toxicity is peripheral neuropathy, which occurred in 15%
       of stavudine versus 6% of zidovudine-treated patients for 80 weeks in a
       randomized, blinded, phase III trial. Stavudine-treated groups have
       experienced significant increases in mean CD4 cell counts and decreases
       in both mean serum p24 antigen levels and infectious HIV titers in
       peripheral blood mononuclear cells. In subjects with prior zidovudine
       treatment, the duration of these responses is limited; CD4 counts and
       serum p24 antigen levels return to baseline after approximately 6
       months. The effect of stavudine on clinical outcome and survival has not
       yet been established in comparative trials. Stavudine offers an
       additional therapeutic option to those individuals who are refractory to
       or intolerant of other available antiretrovirals.
 DE    Animal  Antiviral Agents/ADVERSE EFFECTS/*PHARMACOLOGY  Clinical Trials
       Human  HIV-1/*DRUG EFFECTS/GENETICS  Reverse Transcriptase
       Inhibitors/ADVERSE EFFECTS/*PHARMACOLOGY  Stavudine/ADVERSE
       EFFECTS/*PHARMACOLOGY  JOURNAL ARTICLE  REVIEW  REVIEW, TUTORIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

